CVS Health Corp. (CVS) Stock Valuation — DCF Analysis
Medical - Healthcare Plans · NYSE
Current Price
$103.58
Intrinsic Value
$149.65
+30.8% margin of safety
COMPETITIVE MOAT
↑Integrated Healthcare Ecosystem
CVS Health's unique integration of retail pharmacies, PBM services, and health insurance creates a powerful ecosystem. This allows for cross-selling opportunities and data synergy, driving customer loyalty and operational efficiencies.
↑Scale and Network Effects
With a vast network of retail locations and a large member base across its insurance plans, CVS benefits from significant scale. This scale provides negotiating power with providers and suppliers, creating a barrier to entry for smaller competitors.
↑Brand Recognition and Trust
CVS has established a strong and trusted brand in the healthcare sector. This recognition fosters customer loyalty and makes it a preferred choice for individuals seeking pharmacy and health insurance services.
INVESTMENT RISKS
↓Intensifying Competition
The healthcare industry is highly competitive, with players like UnitedHealth Group leveraging AI for efficiency. CVS faces pressure from both traditional insurers and emerging tech-focused healthcare disruptors.
↓Regulatory and Policy Changes
Healthcare is subject to significant government regulation and policy shifts. Changes in reimbursement rates, drug pricing, or insurance mandates could negatively impact CVS's profitability and business model.
↓Rising Healthcare Costs
While recent trends show softer medical costs, the long-term trajectory of healthcare expenses remains a concern. Unexpected increases in medical utilization or costs could strain CVS's insurance margins.
Base case
CVS base case valuation
A base case discounted cash flow model for CVS estimates an intrinsic value of about $149.65 per share, against a current price of $103.58. The model assumes 12.8% annual free cash flow growth, a 10.0% discount rate, and a 18x exit multiple.
Intrinsic Value
$149.65
Margin of safety
+30.8%
Expected annual return
+7.6%
Base case assumptions: 12.8% annual growth, 10.0% discount rate, 18x exit multiple, 5 year projection. Data as of 2026-06-29.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the CVS valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for CVS Health Corp. respond.
Open DCF Calculator for CVSCompany Overview
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
Financial Metrics — CVS Stock Valuation Data
Revenue/Share (TTM)
$320.43
FCF/Share (TTM)
$5.81
ROIC (TTM)
2.9%
ROE (TTM)
3.9%
P/FCF
17.9x
EV/EBITDA
18.1x
FCF Yield
5.59%
Debt/Equity
1.01x
Based on trailing twelve-month data, CVS shows a free cash flow per share of $5.81 and a ROIC of 2.9%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 17.9x and FCF yield of 5.59% are important context metrics when evaluating CVS's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of CVS?
CVS Health Corp. currently generates $5.81 in free cash flow per share. At the current price of $103.58, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is CVS undervalued?
CVS trades at a P/FCF ratio of 17.9x with a free cash flow yield of 5.59%. This P/FCF is in a moderate range. However, whether CVS is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value CVS stock using DCF?
To perform a DCF valuation on CVS Health Corp.: (1) Start with the trailing free cash flow per share ($5.81) as the base, (2) project future FCF growth over 5-10 years based on Medical - Healthcare Plans industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting CVS's risk profile — with a debt-to-equity of 1.01x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to CVS?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For CVS Health Corp., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Healthcare Plans trends, then discounting those amounts to today's dollars. CVS's ROIC of 2.9% suggests the company may face challenges generating returns above its cost of capital.
How does WACC affect CVS stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For CVS, with a debt-to-equity ratio of 1.01x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 18.1x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See CVS PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value CVS with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-06-29. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.